Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 in Initial Severe ITP
NCT06686927Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of romiplostim in primary immune thrombocytopenia (ITP). Started Nov 2024; status: recruiting.
02
Drugs
romiplostim
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06686927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686927.